INTRODUCTION:

Flunarizine dihydrochloride [FLU] chemically is (E)1[Bis(4fluorophenyl)methyl]-4-(3-phenyl-2-propenyl) piperazine dihydrochloride. It is a calcium channel blocker which reduces arterial and arteriolar smooth muscle spasm by reducing intracellularCa2+ overload due to brain hypoxia. It is used in migraine prophylaxis and also as antihistaminic and sedative. FLU and PRO are official in B.P.¹ and I.P.² respectively. Propranolol HCl [PRO] chemically is (2RS)-1-[(1methylethyl) amino]-3-(1- naphthalenyloxy)-2-propanol hydrochloride. It is a non-selective beta blocker, that is, it blocks the action of epinephrine on both β1- and β2-adrenergic receptors. It is used for the treatment of angina pectoris, cardiac arrhythmia, hypertension, anxiety attacks, migraine prophylaxis and glaucoma. FLU and PRO these drugs are used in combination for migraine prophylaxis³. Literature survey reveals that various analytical methods like UV^4-5, HPLC^6-8, HPTLC⁹ and GC¹⁰ are reported for the individual drug and in combination with others.

Therefore, in the present work a successful attempt has been made to estimate both these drugs simultaneously by UV spectrophotometric absorbance correction method using methanol and 0.1N HCl. The present paper describes a simple, accurate, precise and economic method for simultaneous determination of FLU and PRO in combined capsule dosage form.

MATERIALS AND METHOD:

Instrument, chemicals and reagents:

Pure drugs of FLU and PRO were procured as gift samples from FDC India Ltd. and Ipca Laboratories Ltd. Mumbai, India respectively. A.R. Grade Methanol from LOBA Chem, was used as the solvent for preparing solutions. The solution of 0.1N HCl was prepared in double distilled water as per IP 1996 procedure. The commercial formulation of FLU and PRO in ratio 1:4 (Betacap plus 10, FLU 10 mg and PRO 40 mg per capsule) were purchased from local market. The instrument used was Shimadzu double beam UV/Vis spectrophotometer model V- 1800. (UV Probe 2.32 software). Weighing was done on electronic single pan weighing balance (Make: Shimadzu Model: AX 200). Standard stock solutions 1 mg/ml of FLU and PRO were prepared separately in methanol. The aliquot portions of standard stock solutions of FLU and PRO were diluted with 0.1N HCl individually and combination to get series of concentration from 1-25 μg/ml for FLU and 4-100 μg/ml for PRO.

Procedure:

Absorbance correction method is based upon determination of identity, concentration and absorptivity of the absorbing interferents and finaly its contribution is calculated from the total absorbance of the mixture. Solutions of FLU and PRO (10 μg/ml each) were prepared separately by appropriate dilution of standard stock solutions and scanned over the range of 400 to 200 nm.

Figure 1: Overlain spectra of FLU (2 μg/ml) and PRO (8 μg/ml).

From the overlain spectrum (Figure1) the wavelengths selected for estimation of drugs were 288.8 nm as detecting wavelength for PRO and 253.2 nm as detecting wavelength for FLU. Both these drugs obeyed Beers law individually and in mixture within concentration range of 1-25 μg/ml for FLU and 4-100 μg/ml for PRO. The absorptivity values (A 1%, 1 cm) are recorded in Table 1. The sample absorbance, absorptivity and corrected absorbance were determined and finally the concentration of each drug was calculated using following equation

C=A/A (1%, 1 cm)

Where, C, A, A (1%, 1 cm) are the concentration, absorbance and absorptivity at selected wavelengths for selected drugs.

Application of proposed method to marketed formulation:

20 capsules were accurately weighed, average weight was calculated, finely powdered and mixed thoroughly. An accurately weighed capsule powder equivalent to about 2 mg of PRO was transferred to 25 ml volumetric flask. The contents were shaken for 15 minutes with methanol and volume was adjusted upto the mark with same. The solution was filtered through Whatman No.1 filter paper. An accurately measured 1 ml portion of filtrate was further diluted to 10 ml with 0.1 N HCl. The absorbance of the above solution was then measured at 288.8 nm and 253.2 nm in 1 cm cell against 0.1 N HCl as blank. Five replicate estimations were done in similar way. The contents of FLU and PRO were calculated and % label claim was determined. Observations and results of estimation of FLU and PRO in marketed formulation analysis are given in Table 2.

Table1 : (A 1%, 1 cm) values of FLU and PRO at selected wavelengths

Sr No.	FLU	PRO
Sr No.	262.5 nm	262.5 nm	288.8 nm
1	330	90.0	216.7
2	325	91.2	217.5
3	326.6	90.8	216.6
4	325	90.6	216.2
5	326	91.0	217
Mean± S.D.	326.52± 2.06203	90.72± 0.46043	216.8± 0.48476

Validation:

Validation of proposed method was carried out for the following parameter as per ICH/USP 16 guidelines. Accuracy of the proposed method was ascertained on the basis of recovery studies, performed by standard addition method. Accurately weighed quantities of preanalysed capsule content equivalent to 2 mg was taken in series of 25 ml volumetric flask and to them known amount of FLU and PRO were added at different concentration levels so as to produce solutions containing 80%, 100% and 120% of the label claim. Percentage recovery was calculated. The results are shown in Table 3. Precision of the above method was ascertained by replicate estimation of drugs for marketed formulation. The results are shown in Table 2.

The ruggedness of the method was studied under three different parameters. Intraday variation (samples were analysed at different times on the same day), Interday variation (samples were analysed at three different days 1^st, 3^rd and 5^th day ) and different analyst (samples were analysed by three different analysts as per the proposed method). The results are shown in Table 4.

Table 2: Observations and results of marketed formulation analysis

Sr. no.	Wt of capsule content(gm)	Absorbance		% Label claim
		253.2 nm	288.8 nm	FLU	PRO
1	0.00745	0.138	0.174	99.23	99.98
2	0.00743	0.136	0.172	97.50	99.12
3	0.00746	0.139	0.175	100.09	100.46
4	0.00744	0.137	0.172	98.86	98.99
5	0.00747	0.135	0.170	96.97	97.47
Mean± S.D. R.S.D.				98.53± 1.2774 0.01296	99.20± 1.1444 0.01154

Table 3 Observations, results and statistical data for recovery studies

Sr. No.	Wt of capsule powder(gm)	Amount added μg/ml		Absorbance		% Recovery
		FLU	PRO	262.5 nm	288.8 nm	FLU	PRO
1	0.00745	1.6	6.4	0.250	0.312	99.73	99.59
2	0.00747	2	8	0.276	0.346	99.71	99.15
3	0.00744	2.4	9.6	0.306	0.380	99.86	99.41
Mean± S.D. R.S.D.						99.76± 0.08145 0.0008	99.38± 0.2212 0.00223

Table 4 results of Ruggedness studies of proposed method

Parameters	FLU* (Mean± S.D.)	PRO* (Mean± S.D.)
Intraday	98.55±1.44	100.17±1.43
Interday	97.10±1.69	98.93±1.43
Different analyst	98.81±1.29	99.52±0.8137

*Results are mean of three determinations, S.D. is standard deviation

For linearity and range capsule powder in the range of 80%-120% of test concentration of label claim was taken. The absorbance of final solutions were read at 253.2 nm and 288.8 nm and a graph was plotted as % test concentration Vs absorbance. FLU and PRO were found to be linear in the range of the test concentration.

Figure2: Plot of linearity and range

RESULTS AND DISCUSSION:

An accurate, rapid, sensitive and economic method for the simultaneous analysis of FLU and PRO was developed. Accuracy of the proposed method was ascertained by recovery studies.% recoveries with standard deviation were found to be 99.76±0.08 and 99.38±0.22 for FLU and PRO respectively. The proposed method was also successfully applied to pharmaceutical formulation. No interference was observed from the pharmaceutical adjuvants. The results of marketed formulation analysis were in good agreement with labelled amounts indicating high degree of precision

CONCLUSION:

The applicability for the proposed method for quantitative estimation of FLU and PRO in commercial formulation gave accurate and precise results. Due to high sensitivity and simple sample preparation can be the part of undergraduate curriculum. Moreover spectrophotometric methods have obvious advantage over sophisticated instrumental analysis. Hence simple, economical and less time consuming spectrophotometric methods always have a role in routine pharmaceutical analysis.

ACKNOWLEDGEMENTS:

The authors are gratefully acknowledging FDC India Ltd. Mumbai for providing the gift sample of FLU and Ipca Laboratories Ltd Mumbai, India for providing the gift sample of PRO. Authors are also thankful to Vidyabharati College of Pharmacy, Amravati for providing necessary fascilities for the research work.

REFERENCES:

1 British Pharmacopoeia, The Department of Health, published by The Stationery office onbehalf of medicines and Health Care Products Regulatory Agency, 2007,Vol. I, 890-891.

2 Indian Pharmacopoeia, Government of India, Ministry of Health and Family Welfare, published by The Indian pharmacopoeia commission Ghaziabad, 2010,Vol. III, 1987-1988.

3. Schmidt R. and Oestreich W. Flunarizine in Migraine Prophylaxis. The Clinical Experience, Journal of Cardiovascular Pharmacology, 1991, 18, 21-26.

4. Jain S. K., Jain D., Tiwari M., and Chaturvedi S.C. Simultaneous spectrophotometricestimation of propranolol hydrochloride and hydrochlorthiazide in pharmaceutical formulation, Indian J. Pharm.Sci.,2002 , 64, 267- 270.

5. Mohammad M.A.A. Spectrophotometric and Spectrofluorimetric determination of Cinnarizine and flunarizin/ dihydrochloridein pure and dosage forms, Bull Fac. Pharm. Cairo University, 2004,42, 27-40.

6. Jończyk A. and Nowakowska Z. Determination of hydrochlorothiazide, triamterene andpropranolol hydrochloride by the spectrophotometric method and highperformance liquidchromatography (HPLC), Acta Pol Pharm., 2001 58,339-344.

7. Wahbi A.A., El-WalilyA.F., Hassan E.M., Saliman F.G., El-Gendi A.J., Liquid chromatographic determination of flunarizine dihydrochloride in the presence of its degradation product, PharmBiomed Anal., 1995,13, 77-84.

8. Kartinasari W.F., Chufianty H. and Indrayanto G. HPLC determination of Flunarizine dihydrochloridein Tablets and Its Validation, Journal of Liquid Chromatography and Related Technologies, 2003, 26, 1059-1067.

9. Bhavar G. and Chatpalliwar V.A. Quantitative Analysis of Propranolol Hydrochloride by High Performance Thin Layer Chromatography, Indian J Pharm Sci., 2008, 70, 395–398. 10.

10. Salle E. D., Baker K.M., Bareggi S.R., Watkins W.D.,. Chidsey C.A., Frigerio A., Morselli P.L.A sensitive gas chromatographic method for the determination of propranolol in human plasm, Journal of Chromatography A,1973, 84, 347-353.

Received on 12.04.2013 Modified on 19.04.2013

Asian J. Research Chem. 6(5): May 2013; Page 506-508